News & Updates
Filter by Specialty:
HCV reinfection highest among people with ongoing injecting drug use
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.
HCV reinfection highest among people with ongoing injecting drug use
14 Aug 2022
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
12 Aug 2022
Another breakthrough for HIV: Fourth patient goes into long-term remission
Hope springs yet again in the field of HIV treatment, as another HIV patient (reportedly the fourth in the world) goes into remission 3 decades following diagnosis. The patient stopped antiretroviral therapy (ART) after receiving allogeneic hematopoietic stem cell transplantation (HCT) of CCR5-Δ32/Δ32 donor cells for acute myelogenous leukaemia (AML).
Another breakthrough for HIV: Fourth patient goes into long-term remission
12 Aug 2022
Teclistamab demonstrates clinical activity for R/R MM
The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.
Teclistamab demonstrates clinical activity for R/R MM
11 Aug 2022
Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.
Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
11 Aug 2022
1 week off methotrexate works okay for RA patients receiving flu shot
Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.